afabicin (Debio 1450)


afabicin (Debio 1450), is a new antibiotic benefiting from both oral and IV formulations. It is a highly potent, staphylococcus-selective antibiotic with a low propensity to emergence of resistance. This first-in-class FabI inhibitor retains its activity on staphylococci strains resistant to antibiotics currently in clinical use including beta lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, will now be studied in Bone & Joint infections (BJIs) caused by staphylococci.

Press Releases

All Press Releases


All Publications